146 related articles for article (PubMed ID: 38129782)
1. Preliminary evidence for endoscopic surgery combined with postoperative anti-PD-1 immunotherapy in advanced recurrent nasopharyngeal carcinoma.
Xu H; Li W; Zhang H; Wang H; Hu L; Gu Y; Wang D
BMC Cancer; 2023 Dec; 23(1):1259. PubMed ID: 38129782
[TBL] [Abstract][Full Text] [Related]
2. Endoscopic surgery versus intensity-modulated radiotherapy in locally advanced recurrent nasopharyngeal carcinoma: a multicenter, case-matched comparison.
Liu Y; Huang N; Gao J; He B; Huang H; Wan L; Cai Q; Zhu Z; Zhou S; Wang J; Wang X; Qiu Q; Han F
J Otolaryngol Head Neck Surg; 2023 Nov; 52(1):72. PubMed ID: 37932841
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic Nasopharyngectomy Combined With Internal Carotid Artery Pretreatment for Recurrent Nasopharyngeal Carcinoma.
Wang ZQ; Xie YL; Liu YP; Zou X; Chen JH; Hua YJ; Gu YK; Ouyang YF; Yu ZK; Sun R; Huang PY; Chen MY
Otolaryngol Head Neck Surg; 2022 Mar; 166(3):490-497. PubMed ID: 34182810
[TBL] [Abstract][Full Text] [Related]
4. Salvage endoscopic nasopharyngectomy is superior to intensity-modulated radiation therapy for local recurrence of selected T1-T3 nasopharyngeal carcinoma – A case-matched comparison.
You R; Zou X; Hua YJ; Han F; Li L; Zhao C; Hong MH; Chen MY
Radiother Oncol; 2015 Jun; 115(3):399-406. PubMed ID: 25987536
[TBL] [Abstract][Full Text] [Related]
5. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
Liu YP; Wen YH; Tang J; Wei Y; You R; Zhu XL; Li J; Chen L; Ling L; Zhang N; Zou X; Hua YJ; Chen YM; Chen L; Lu LX; Chen MY; Wen WP
Lancet Oncol; 2021 Mar; 22(3):381-390. PubMed ID: 33600761
[TBL] [Abstract][Full Text] [Related]
6. Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma.
Liu YP; Lv X; Zou X; Hua YJ; You R; Yang Q; Xia L; Guo SY; Hu W; Zhang MX; Chen SY; Lin M; Xie YL; Liu LZ; Sun R; Huang PY; Fan W; Guo X; Hong MH; Chen MY
Cancer Commun (Lond); 2019 Nov; 39(1):75. PubMed ID: 31730020
[TBL] [Abstract][Full Text] [Related]
7. A novel endoscopic nasopharyngectomy by low-temperature plasma radiofrequency ablation in localized recurrent nasopharyngeal carcinoma.
Zou X; Feng ZK; Hua YJ; Liu YP; Xie YL; Ouyang YF; Liu YL; Wang ZQ; You R; Ding X; Yang Q; Yu ZK; Huang PY; Wang SL; Chen MY
Head Neck; 2024 Feb; 46(2):291-299. PubMed ID: 37974339
[TBL] [Abstract][Full Text] [Related]
8. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Endoscopic Nasopharyngectomy Combined With Low-Dose Radiotherapy for Primary T1-2 Nasopharyngeal Carcinoma.
Zhang B; Li Y; Weng J; Huang B; Ban M; Lan G; Lu Y; Luo J; Qu S; Si Y
Technol Cancer Res Treat; 2021; 20():15330338211011975. PubMed ID: 33896244
[TBL] [Abstract][Full Text] [Related]
10. Salvage Endoscopic Skull Base Surgery: Another Treatment Option After Immunotherapy for Recurrent Nasopharyngeal Carcinoma.
Peng Z; Wang Y; Fang Y; Wang Y; Yuan X; Shuai M; Xie S; Fan R; Zhang H; Xie Z; Jiang W
Front Immunol; 2022; 13():899932. PubMed ID: 35686123
[TBL] [Abstract][Full Text] [Related]
11. Strategies for patients with recurrent nasopharyngeal carcinoma involved internal carotid artery who are intolerant to embolization.
Wu WB; Zhang XB; Feng ZK; Li HF; Liu YP; Liang JL; Xie YL; Hua YJ; Sun R; Wang SL; Chen JH; Chen MY
Rhinology; 2024 Jun; 62(3):342-352. PubMed ID: 38078376
[TBL] [Abstract][Full Text] [Related]
12. The role of nasopharyngectomy in the management of nasopharyngeal carcinoma.
Wang WH; Yeh CF; Lan MY
Curr Opin Otolaryngol Head Neck Surg; 2022 Feb; 30(1):3-12. PubMed ID: 34958319
[TBL] [Abstract][Full Text] [Related]
13. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi YR; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Liu Z; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Feng H; Yao S; Keegan P; Xu RH
Nat Med; 2021 Sep; 27(9):1536-1543. PubMed ID: 34341578
[TBL] [Abstract][Full Text] [Related]
14. 5-year outcomes of salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma.
Thamboo A; Patel VS; Hwang PH
J Otolaryngol Head Neck Surg; 2021 Feb; 50(1):12. PubMed ID: 33597031
[TBL] [Abstract][Full Text] [Related]
15. Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy.
Jiang Y; Chen C; Liu G; Fang T; Lu N; Bei W; Dong S; Li W; Xia W; Liang H; Xiang Y
Sci Rep; 2024 Jan; 14(1):1768. PubMed ID: 38242940
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness of endoscopic nasopharyngectomy in locally recurrent rT1-rT3 nasopharyngeal carcinoma: a study based on Markov model].
Chen MY; Wen WP; Li J; Liu YP; Chen MY; Tang J; Wen YH
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Nov; 57(11):1304-1310. PubMed ID: 36404655
[No Abstract] [Full Text] [Related]
17. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
18. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
Jin ZC; Zhong BY; Chen JJ; Zhu HD; Sun JH; Yin GW; Ge NJ; Luo B; Ding WB; Li WH; Chen L; Wang YQ; Zhu XL; Yang WZ; Li HL; Teng GJ;
Eur Radiol; 2023 Dec; 33(12):8669-8681. PubMed ID: 37368105
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis.
Luo J; Xiao W; Hua F; Cao Y; Wang D; Wang X
BMC Cancer; 2023 Nov; 23(1):1172. PubMed ID: 38037076
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
Jung HA; Park KU; Cho S; Lim J; Lee KW; Hong MH; Yun T; An HJ; Park WY; Pereira S; Ock CY; Keam B
Clin Cancer Res; 2022 Oct; 28(19):4240-4247. PubMed ID: 35819451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
